| Date | Title | Description |
| 15.09.2026 | Thyme Care Secures $125M+, Launches New Oncology Venture | Thyme Care, a leading oncology management firm, has secured over $125 million in Series E funding. This substantial investment powers its profitable value-based care model. It also establishes Thyme Companies, a new parent entity. This new ... |
| 14.09.2026 | Thyme Care Closes $125+ Million Series E |
NASHVILLE, TN, Thyme Care, the nationally recognized oncology company, today announced a new Series E financing round of over $125M.
>> Click here for more funding data on Thyme Care
>> To export Thyme Care funding data to PDF ... |
| 18.08.2026 | Abcuro Raises $66M in Series D Funding | Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, raised $66M in Series D funding.
The round was led by New Leaf Ve... |
| 13.08.2026 | Khartis Therapeutics Raises $50M To Advance Oral Immunology Drugs | Khartis Therapeutics Raises $50M Series B
Khartis Therapeutics has raised $50 million in Series B funding to advance its oral medicine pipeline.mForge Life Science Partners led the round. Longwood Fund and Alexandria Venture Investments joi... |
| 15.06.2026 | Stepful Secures $55M to Transform Healthcare Workforce | Stepful just closed a $55 million Series C funding round. This vital investment fuels its mission. It tackles a critical national issue: the dire healthcare labor shortage. The company's AI-powered platform reimagines clinical education. It... |
| 10.06.2026 | Stepful: $55 Million Series C Raised To Expand AI-Powered Healthcare Workforce Training Platform | Stepful announced a $55 million Series C funding round led by Oak HC/FT, with participation from Foresite Capital, Hearst Ventures, the Citi Impact Fund, and existing investors including SemperVirens, Y Combinator, Intermountain Health, and... |
| 09.06.2026 | Stepful Secures $55M to Expand AI-Powered Healthcare Workforce Training | What You Should Know
Healthcare workforce infrastructure leader Stepful has announced a $55M Series C funding round led by premier venture firm Oak HC/FT.
The financing round features strategic backing from new investors Foresite Capital, H... |
| 09.06.2026 | Stepful Raises $55M in Series C Funding | Stepful, a NYC-based provider of a training platform for healthcare careers, raised $55M in Series C funding.
The round was led by Oak HC/FT, with participation from new investors Foresite Capital, Hearst Ventures, and the Citi Impact Fund,... |
| 19.05.2026 | Quince Therapeutics: $187 Million Private Placement And Orphai Acquisition To Advance Pulmonary Disease Pipeline | Quince Therapeutics announced the acquisition of Orphai Therapeutics along with a private placement financing valued at up to $187 million to expand its pulmonary disease pipeline. The acquisition adds Orphai’s lead program, LAM-001, an inh... |
| 03.04.2026 | Lilly покупает британского разработчика лекарства от расстройства сна за $7,8 млрд | Препарат Zepbound компании Eli Lilly & Co. помогает решать одну из самых сложных проблем здравоохранения нашего времени — ожирение. Теперь фармкомпания берется за еще одну серьезную проблему общественного здоровья: расстройства сна.
В с... |
| 30.03.2026 | Pinnacle Medicines Secures $89M Series B: Oral Peptides Advance Clinical Pipeline with AI Power | Pinnacle Medicines, a Doylestown, PA biotech, closed an oversubscribed $89 million Series B funding round. This significant capital injection accelerates its oral peptide therapeutics pipeline. The company targets immunology and cardiometab... |
| 29.03.2026 | Pinnacle Medicines: $89 Million Series B Raised For Oral Peptide Therapeutics Development | Pinnacle Medicines, a biotechnology company focused on oral peptide therapeutics, announced it has closed an oversubscribed $89 million Series B financing round to advance its pipeline into clinical trials. The round was co-led by LAV and F... |
| 26.03.2026 | Pinnacle Medicines Raises $89M in Series B Funding | Pinnacle Medicines, a Doylestown, PA-based biotechnology company developing oral peptide therapeutics, raised $89M in Series B funding.
The round was led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA... |
| 26.02.2026 | Slate Medicines Secures $130M to Advance Migraine Prevention | Slate Medicines secures $130 million in Series A funding. The Raleigh, NC-based biotech company launched to transform migraine prevention. Its core focus is SLTE-1009, an anti-PACAP monoclonal antibody. This therapy addresses severe headach... |
| 24.02.2026 | Slate Medicines: $130 Million Series A Raised To Advance Anti-PACAP Migraine Therapies | Slate Medicines, a privately held biotech company developing next-generation therapeutics for headache disorders, has launched with the close of a $130 million Series A financing and the in-licensing of SLTE-1009, an anti-PACAP monoclonal a... |
| 24.02.2026 | Slate Medicines Raises $130M in Series A Funding | Slate Medicines, a Raleigh, NC-based biotech company, raised $130M in Series A funding.
The round was led by RA Capital Management, Forbion, and Foresite Capital with participation from an additional undisclosed biotech investor.
In conjunc... |
| 05.11.2025 | Indomo: $25 Million Raised To Bring At-Home Injectable Treatment For Acne Into The Mainstream | Boston-based clinical-stage therapeutics company Indomo has announced a $25 million funding round led by prominent investors Atomic, Foresite Capital, and Polaris Partners. The company is developing an at-home injectable therapy for inflamm... |
| 03.11.2025 | Indomo Raises $25M in Funding | Indomo, a Boston, MA-based therapeutics company developing at-home prescription dermatology treatments, raised $25M in total funding.
Backers included Atomic, Foresite Capital, Polaris Partners and others.
The company intends to use the fun... |
| 29.10.2025 | Indomo Emerges from Stealth with $25M for At-Home Injectable Acne Therapy | What You Should Know:
– Indomo, a therapeutics company focused on developing at-home prescription dermatology treatments, today emerged from stealth with $25M in total funding led by leading investors including Atomic, Foresite Capital, and... |
| 03.10.2025 | Avenzo Therapeutics Secures $60 Million Series B to Advance Oncology Breakthroughs | Avenzo Therapeutics secured $60 million in Series B funding. This propels their oncology pipeline. The San Diego biotech now totals $446 million raised. OrbiMed and SR One led the round. New investor Longwood Fund joined. Key existing backe... |
| 29.09.2025 | Thyme Care Secures $97M: Reshaping Value-Based Cancer Care | Thyme Care secured $97M in Series D funding. This boosts its value-based oncology mission. Total capital raised now stands at $275M. The company manages $5B in cancer spend. It serves 8 million people nationwide. Thyme Care leverages AI and... |
| 29.09.2025 | Thyme Care Secures $97 Million Series D To Transform Cancer Care | Thyme Care, a leading innovator in value-based cancer care, has completed a $97 million Series D funding round. This funding demonstrates strong confidence from both existing and new strategic partners, bringing Thyme Care’s total capital r... |
| 26.09.2025 | Thyme Care Secures $97M to Scale Value-Based Oncology and AI Infrastructure | Robin Shah, Co-Founder and Chief Executive Officer; Dr. Bobby Green, Co-Founder, Chief Medical Officer, and President; and Dr. Brad Diephuis, President and Chief Operating Officer
What You Should Know:
– Thyme Care, a value-based cancer car... |
| 25.09.2025 | Thyme Care Raises $97M in Series D Funding | Robin Shah, Co-Founder and Chief Executive Officer; Dr. Bobby Green, Co-Founder, Chief Medical Officer, and President; and Dr. Brad Diephuis, President and Chief Operating Officer
Thyme Care, a Nashville, TN-based value-based cancer care en... |
| 23.09.2025 | Avenzo: $60 Million Series B Secured For Developing Oncology Therapies | Avenzo Therapeutics, a biotechnology company focused on developing new cancer treatments, has announced the closing of a $60 million Series B funding round. This latest investment follows a previous $386 million raised through its Series A ... |
| 22.09.2025 | Avenzo Therapeutics Raised $60M in Series B Funding | Avenzo Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing new oncology therapies, raised $60M in Series B funding.
The round was led by OrbiMed and SR One, with participation from new investor Longwood Fund,... |
| 20.08.2025 | Identifeye HEALTH Launches AI-Powered Retinal Screening Platform for Eye Care | What You Should Know:
-Millions of Americans miss the simple screenings that could preserve their vision. identifeye HEALTH, a medical diagnostics company at the forefront of AI and automation, has officially launched its retinal screening ... |
| 31.03.2025 | Alphabet-Backed Isomorphic Labs Raises $600M For AI Drug Development | 3 Shares Email Facebook Twitter LinkedIn
Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply artificial intelligence to the drug development process.
The new round was led by ... |
| 28.02.2025 | Eikon Therapeutics Secures $350.7 Million to Propel Drug Development | Eikon Therapeutics is on the rise. The Hayward, California-based biotechnology company recently announced a significant milestone: a $350.7 million Series D funding round. This influx of capital is not just a number; it’s a lifeline for inn... |
| 27.02.2025 | Eikon Therapeutics Raises $350.7M in Series D Funding | Eikon Therapeutics, a Hayward, CA-based pivotal-stage biotechnology company for drug discovery and development, raised $350.7M in Series D funding.
The investment syndicate was composed of mutual funds, sovereign wealth funds, and healthcar... |
| 26.02.2025 | Eikon Therapeutics: $350.7 Million (Series D) Raised For Advancing Clinical-Stage Programs | Eikon Therapeutics, a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, announced the initial closing of a $350.7 million Seri... |
| 19.02.2025 | Abcuro: $200 Million (Series C) Raised For Advancing Medicine In Development For Inclusion Body Myositis | Abcuro – a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells – announced the closing of a $200 million Series C financing led by New... |
| 13.02.2025 | Abcuro Raises $200M in Series C Financing | Abcuro, a Newton, MA-based clinical-stage biotechnology company, raised $200M in Series C funding.
The round was led by New Enterprise Associates (NEA) joined by Foresite Capital with participation from existing investors including RA Capit... |
| 14.12.2024 | Pleno: Clinical And Multi-Omics Diagnostics Company Raises $25 Million (Series B) | Pleno, a clinical and multi-omics diagnostics company revolutionizing biological target detection, announced the appointment of Dr. Vik Vaz, M.D., as its new chief executive officer and to serve on its Board of Directors, effective immediat... |
| 13.12.2024 | Pleno's $25M Boost: A New Era in Multi-Omics Diagnostics | In the bustling world of biotechnology, Pleno has just made waves. The San Diego-based company secured $25 million in Series B funding, a significant leap forward in its mission to revolutionize diagnostics. This infusion of capital comes f... |
| 12.12.2024 | Pleno Closes $25M Series B & Appoints Dr. Vik Vaz as CEO | Dr. Vik Vaz, CEO at Pleno
What You Should Know:
– Pleno, an innovative multi-omics diagnostics company, announced it has raised $25M in Series B funding and appointed Dr. Vik Vaz as its new Chief Executive Officer (CEO). Key investors Deerf... |
| 08.12.2024 | Sollis Health: Concierge Medicine Provider Company Secures $33 Million (Series B) | Sollis Health, which is the first concierge medicine provider to offer its members 24/7 access to ER-level diagnostics and capabilities, announced the completion of a $33 million Series B funding round, led by Foresite Capital with particip... |
| 05.12.2024 | Sollis Health Raises $33M in Series B Funding | Sollis Health, a NYC-based concierge medicine provider, raised $33M in Series B funding.
The round was led by Foresite Capital with participation from Torch Capital, Montage Ventures, Friedom Partners, Read Capital, and One Eight Capital, a... |
| 04.12.2024 | Maze Therapeutics Secures $115 Million to Revolutionize Kidney Disease Treatment | Maze Therapeutics, a beacon of innovation in the biopharmaceutical landscape, has successfully raised $115 million in a Series D financing round. This funding marks a significant milestone for the South San Francisco-based company, which is... |
| 03.12.2024 | Maze Therapeutics Raises $115M in Series D Financing | Maze Therapeutics, a South San Francisco, CA-based clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic disease... |
| 03.12.2024 | Maze Therapeutics: $115 Million (Series D) Raised To Develop Precision Medicine | Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, announced the ... |
| 22.10.2024 | Seaport Therapeutics: $225 Million (Series B) Raised To Advance Novel Neuropsychiatric Medicines | Seaport Therapeutics—a clinical-stage biopharmaceutical company advancing novel neuropsychiatric medicines with a proven strategy and team—announced the closing of an oversubscribed $225 million Series B financing round. General Atlantic, a... |
| 21.10.2024 | Seaport Therapeutics Closes $225M Series B Financing Round | Seaport Therapeutics, a Boston, MA-based biopharmaceutical company that is developing novel neuropsychiatric medicines, raised $225M in Series B funding.
The round, which brought the total amount to $325M, was led by General Atlantic, with ... |
| 13.09.2024 | These Female Founders And CEOs Raised The Biggest Rounds In 2024 | 6 Shares Email Facebook Twitter LinkedIn
When measuring funding to startups with female founders and CEOs, the perennial takeaway is that women remain underrepresented. Last year, for instance, just 3% of U.S. funding went to startups with ... |
| 25.07.2024 | Canadian Startups Surge: Clio and Third Arc Bio Lead the Charge**
** | ** In the world of startups, the spotlight often shines brightest on Silicon Valley. Yet, this week, Canadian startups have taken center stage, proving that innovation knows no borders. Two companies, Clio and Third Arc Bio, have made headl... |
| 25.07.2024 | Element Biosciences: A New Era in DNA Sequencing**
** | ** Element Biosciences is on a mission. The San Diego-based company is reshaping the landscape of DNA sequencing and multi-omics technology. With a recent infusion of over $277 million in Series D funding, Element is poised to democratize a... |
| 23.07.2024 | Third Arc Bio launches with $165M to address unmet needs in oncology and autoimmunity | The company was founded by executives from Johnson & Johnson
Third Arc Bio is a company that says its on mission to deliver transformational therapies for solid tumors and inflammatory & immunology diseases through the use of multif... |
| 23.07.2024 | Element Biosciences: Over $277 Million In Series D Raised For Democratizing Access To Advanced Biological Tools | Element Biosciences, a developer of pioneering technologies to empower science, announced over $277 million in Series D funding to support its growing global customer base with disruptive DNA sequencing and multi-omics technologies for year... |
| 18.07.2024 | Thyme Care Revolutionizing Cancer Care with $95M Funding Boost | Thyme Care, a game-changer in value-based cancer care, secures a whopping $95M in funding to expand its innovative platform and make waves in the healthcare industry.
Thyme Care, a leading player in the value-based cancer care arena, has ju... |
| 17.07.2024 | Thyme Care Secures $95M to Expand Value-Based Cancer Care Platform | What You Should Know:
– Thyme Care, a leading value-based cancer care enabler raises $95M in funding capital led by Concord Health Partners, with participation from existing investors including CVS Health® Ventures, Town Hall Ventures, a16z... |
| 26.06.2024 | CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He | BEIJING, June 26, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and ... |
| 20.06.2024 | Foresite Capital: Healthcare And Life Sciences Firm Closes Sixth Fund At $900 Million | Foresite Capital, a multi-stage healthcare and life sciences investment firm with over $3.5 billion under management, announced that it has closed its sixth fund with $900 million in capital commitments. And with this new fund, Foresite Cap... |
| 12.06.2024 | Foresite Capital Closes $900M Fund Targeting Precision Medicine & Innovation | What You Should Know:
– Foresite Capital, a San Francisco, CA-based healthcare and life sciences investment firm, announced today the successful closing of its sixth fund with a significant $900M in capital commitments. This new fund fuels ... |
| 12.06.2024 | Foresite raises $900M to make big bets in ‘one of the best biotech investment environments’ | - |
| 26.06.2023 | Pharvaris obtains $70 million in a private placement round | |
| 07.03.2022 | Amid pandemic boom, gaming gets another nod with $750 million new fund | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Shut in at home for stints, oftentimes with little or no face-to-face interaction with the outsid... |
| 07.03.2022 | Foresite Capital Raises $173M Fund for Foresite Labs Incubated Companies | What You Should Know:
– Foresite Capital is announcing their latest, oversubscribed $173M fund, which will be used to support Foresite Labs’ incubated life science companies.
– Foresite Labs was created in October 2019 to found, build, and ... |
| 04.03.2022 | Foresite Capital Raises $173 Million to Fund Foresite Labs Incubated Life Science Companies | The fund allows the firm to provide additional capital to companies in the Foresite Labs incubator program to help them scale and solve the biggest unmet needs in healthcare
–Foresite Capital, a multi-stage healthcare and life sciences inve... |
| 04.03.2022 | Foresite Capital Raises $173M to Fund Foresite Labs Incubated Life Science Companies | Foresite Capital, a San Francisco, CA-based multi-stage healthcare and life sciences investment firm, raised a $173 million fund.
The vehicle will further invest in companies launched by Foresite Labs incubator program to help them scale an... |
| 03.03.2022 | Foresite Capital Raises $173 Million to Back Life-Sciences Incubator Startups | Life-sciences investor Foresite Capital said it has raised $173 million for its first venture fund devoted to startups emerging from an incubator it created to use data science to tackle healthcare challenges.
Foresite Capital, a multistage... |
| 02.03.2021 | Foresite Capital raises $969m | - |
| 27.02.2021 | US-based Investment Firm Foresite Capital raises US$ 969M to invest in Healthcare startups | US-based Foresite Capital, an investment firm that provides catalytic capital to transformative healthcare companies at all stages, raised funding totalling US$ 969 million in commitments from LPs. |
| 26.02.2021 | Foresite Capital Closes Fifth Fundraise, At $969M | Foresite Capital, a San Francisco, CA-based multi-stage healthcare and life sciences investment firm, closed its fifth fundraise with $969m in capital commitments.
The offering comprises:
Foresite Capital Fund V, L.P., and
Foresite Capital ... |
| 26.02.2021 | StartUPDATES: New developments for healthcare startups | Outcomes4Me Inc., developer of a free mobile app and platform to navigate cancer treatment and care, is expanding its patient offering with a medication tracker that makes regimens a core part of the app experience. When adding a medication... |
| 25.02.2021 | Biotech and healthtech firm Foresite Capital raises $969M new fund | The firm, which now has over $4 billion in assets under management, invests across all stages
The biotech space has been growing in the last few years: according to Pitchbook, the space was on track to see more than $20 billion invested in ... |
| 25.02.2021 | Foresite Capital raises $969 million fund to invest in healthcare startups across all stages of growth | - |
| 25.02.2021 | Life Sciences Venture Investor Foresite Capital Raises $969 Million | Life sciences venture investor Foresite Capital has raised $969 million through two new funds after placing successful bets on emerging industries such as biotechnology, genomics and synthetic biology.
San Francisco-based Foresite raised $7... |
| 25.02.2021 | 10X GENOMICS, INC.
10x Genomics : Foresite Capital raises nearly $1 bln for healthcare bets | Feb 25 (Reuters) - U.S. investment firm Foresite Capital said on Thursday it had raised $969 million to invest in healthcare companies, making it the firm's largest fundraise to-date.
The announcement comes on the heels of several other lar... |
| 25.02.2021 | 10x Genomics : Foresite Capital raises nearly $1 bln for healthcare bets | Feb 25 (Reuters) - U.S. investment firm Foresite Capital said on Thursday it had raised $969 million to invest in healthcare companies, making it the firm's largest fundraise to-date.
The announcement comes on the heels of several other lar... |
| 25.02.2021 | Foresite Capital raises $969 million fund to invest in healthcare startups across all stages of growth | Health and life science specialist investment firm Foresite Capital has raised a new fund, its fifth to date, totaling $969 million in commitments from LPs. This is the firm’s largest fund to date and was oversubscribed relative to its orig... |
| 04.02.2021 | 23andMe, Inc. announced that it expects to receive $250 million in funding from Fidelity Management & Research Company LLC, Altimeter Capital Management, LP, Casdin Capital, LLC, Foresite Capital ... | 23andMe, Inc. announced that it has entered into an subscription agreement to issue 25,000,000 class A common shares at issue price of $10 per share for gross proceeds of $250,000,000 on February 4, 2021. The transaction will include partic... |
| 03.12.2020 | Everlywell Secures $175M to Expand Position in At-Home Testing Market | What You Should Know:
– Everlywell secures $175M in Series D funding to expand its virtual care offerings, scale its testing and infrastructure, drive clinical research and disease management through testing, and grow its national leadershi... |
| 19.11.2020 | Pharvaris Announces $80 Million Series C Financing | Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic condition with symptoms that include episodes of debilitating and often painful swelling in the hands, feet, face (lips and tongue), gastrointestinal tract, urog... |
| 19.11.2020 | Pharvaris Announces $80 Million Series C Financing | |
| 21.07.2020 | Foresite Capital Joins $65M Series B Financing for Cerevance | BOSTON, July 21, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April. Wi... |
| 20.11.2019 | GenapSys Nabs $90M to Commercialize Its Breakthrough Electronic Gene Sequencer | – GenapSys launches first-of-its-kind electronic gene sequencer as well as the completion of a $90M series C funding round led by top biotech investor Foresite Capital.
– GenapSys is the first & only to use direct electronic sequencing ... |
| 27.02.2019 | Pharma and biotech should embrace ‘Medicare for all,’ not defeat it | As a growing pantheon of Democratic politicians pledge their support for “Medicare for all” and its variants, the pharmaceutical and biotechnology industries are gearing up for an epic and expensive battle to kill these proposals.
As someon... |
| 07.06.2018 | TPG Leads $85M Series C for SutroVax | SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, today announced the closing of an upsized $85 million Serie... |
| 07.05.2018 | Term Sheet — Monday, May 7 | DUEL IT OUT
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
Any day now, the Supreme Court is expected to decide if the state can legalize sports betting. The court is deliberating on NCA... |
| 05.05.2018 | AI researcher from Alphabet’s Calico Labs launches startup applying machine learning to drug discovery | To enable the machine learning, we will use high-quality data that has already been collected, but we will also invest heavily in the creation of our own datasets using high throughput experimental approaches, datasets that are designed exp... |
| 05.05.2018 | A life sciences firm run by a top VC and a cofounder of Alphabet’s life sciences arm, just raised its biggest fund yet | There’s no end to the number of fascinating devices and therapies being created right now in the fields of health and life sciences. The investors behind them are often pretty interesting, too, given the expertise needed to make informed be... |
| 04.05.2018 | Term Sheet — Friday, May 4 | BLOODBATH
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
— $150 million: The Walton Family, heirs to Walmart Founder Sam Walton
— $125 million: Rupert Murdoch, executive chairman of News Cor... |
| 03.05.2018 | Healthcare-focused Foresite Capital raises $668 mln for data-driven approach | - |
| 03.05.2018 | Foresite Capital Closes Fourth Healthcare and Life Sciences Fund, at $668M | Dr. Jim TananbaumForesite Capital, a San Francisco, CA-based multi-stage healthcare and life sciences investment firm, closed its fourth and largest fund, with $668m in capital commitments.
Limited partners in Fund IV include new investors ... |
| 03.05.2018 | Foresite Capital closes oversubscribed $668M venture fund | Foresite Capital surpassed its $650 million goal to close its largest fund yet, with $668 million in capital commitments. While the firm doesn't limit itself by therapeutic area, it will pay particular attention to companies using data scie... |
| 03.05.2018 | Foresite Capital Closes $668 Million Fund, its Largest Yet | - |
| 28.02.2018 | CRISPR Startup Inscripta Raises $55.5m Series C to Democratize Gene-Editing | Inscripta (formerly Muse Bio) has raised a $55.5 million Series C round led by healthcare investor Mérieux Développement and Washington, DC-based private equity firm Paladin Capital Group. Existing investors Venrock, Foresite, MLS Capital, ... |
| 18.09.2017 | LifeMine Therapeutics Closes $55M Series A | LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite Capital, GV (formerly Google Ventures), Arch Ventures, Boy... |
| 18.09.2017 | Arch Ventures Joins $55M Series A for LifeMine Therapeutics | LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite Capital, GV (formerly Google Ventures), Arch Ventures, Boy... |
| 10.09.2017 | Foresite Capital Leads $55M Series B for Replimune | Replimune Group Inc., a biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 million Series B financing. The proceeds of the financing will primarily be used to gener... |
| 25.07.2017 | Foresite Capital Joins $42M Series B for VenatoRx Pharmaceuticals | MALVERN, Pa.--(BUSINESS WIRE)--VenatoRx Pharmaceuticals, Inc., a biopharmaceutical company developing next-generation antibiotics, today announced that it has raised $42 million in a Series B financing led by Versant Ventures and joined by ... |
| 25.04.2017 | HealthVerity Raises $10M Series B Led by Flare Capital and Greycroft | Center City-based health IT startup HealthVerity announced today it has closed a Series B round totaling $10 million.
The investment was led by Boston-based Flare Capital Partners and NYC/LA Greycroft Partners. Both firms also led that $7.2... |
| 25.04.2017 | HealthVerity Raises $10M Series B Led by Flare Capital and Greycroft | Center City-based health IT startup HealthVerity announced today it has closed a Series B round totaling $10 million.
The investment was led by Boston-based Flare Capital Partners and NYC/LA Greycroft Partners. Both firms also led that $7.2... |
| 25.04.2017 | Term Sheet — Tuesday, April 25 | MONEY-LOSING HOUSE OF HORRORS
Contrarian: The message around Cloudera’s IPO, which is expected to price on Thursday after the market closes, has been yikes. The company was last valued at $4.1 billion; its share pricing values the company a... |
| 25.04.2017 | HealthVerity raised a $10 million Series B | Center City-based health IT startup HealthVerity announced today it has closed a Series B round totaling $10 million.
The investment was led by Boston-based Flare Capital Partners and NYC/LA Greycroft Partners. Both firms also led that $7.2... |
| 23.02.2017 | Term Sheet — Thursday, February 23 | Cirque du LBO
Fortune’s latest feature story, published this morning by my colleague Michal Lev-Ram, is about what happens when private equity takes over the circus. Specifically, TPG Capital and Cirque du Soleil, which the firm acquired in... |
| 09.09.2015 | Daily funding roundup - September 9, 2015 | Didi Kuaidi scored $1B; Chef bagged $40M; Primus Power raised $25M
The battle for supremacy among e-hailing services in China is heating up, and fast. In the same week that Uber revealed that it has raised an additional $1.2 billion to expa... |
| 01.09.2015 | Daily funding roundup - September 1, 2015 | IDG nabbed $120M; Cequr raised $100M; Cloud Apps Capital Partners bagged $53.7M
Cloud business software companies are currently in a strange position when it comes to venture capital. They require more capital and board support than the see... |
| 29.07.2015 | Daily funding roundup - July 29, 2015 | Twilio closed $130M; Mereo BioPharma secured $119; AltspaceVR raised $10.3M
AltspaceVR, a software company that uses virtual reality to provide a new communication platform, raised a $10.3 million round of funding. Investors in the round in... |
| 29.07.2015 | Foresite Capital Closed Fund III at $450M | Foresite Capital, a healthcare growth equity firm, closed its Fund III, at $450m.
Foresite Capital Fund III will continue to execute the firm’s strategy of financing emerging leaders across all healthcare sectors in both the private and pub... |
